Supplementary materials: Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver

These are peer-reviewed supplementary materials for the article 'Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver' published in the Journal of Comparative Effectiveness Research.Supplementary figure A: Median overall survival in the whole cohort according to the treatment modality after propensity score matching.Supplementary figure B: Overall survival according to the treatment modality after excluding patients with 90-day mortality of most definitive primary site surgery after propensity score matching.Supplementary figure C: Median overall survival comparison between single agent and multiagent chemotherapy after propensity score matching.Supplementary figure D: Median overall survival comparison between adjuvant and neoadjuvant chemotherapy after propensity score matching.Supplementary figure E: Median overall survival according to the treatment modality in (A) MSI-H and (B) MSI-L.Supplementary figure F: Median overall survival comparison between single agent and multiagent chemotherapy in (A) MSI-H and (B) MSI-L.Supplementary figure G: Median overall survival comparison between adjuvant and neoadjuvant chemotherapy in (A) MSI-H and (B) MSI-L.Supplementary Table A: Baseline characteristics of metastatic CRC patients with liver metastases according to the treatment modality after propensity score matching.Supplementary Table B: Baseline characteristics of metastatic CRC patients with liver metastases excluding patients with 90-day mortality of most definitive primary site surgery according to the treatment modality after propensity score matching.

本数据集为发表于《比较疗效研究杂志》的论文《围手术期化疗对肝转移性结直肠癌患者生存结果的影响》的同行评审补充材料。补充图A：根据倾向得分匹配后的治疗方式，全队列的中位总生存期。补充图B：在倾向得分匹配后，排除术后90天内死亡的患者，根据治疗方式的总生存期。补充图C：在倾向得分匹配后，单药化疗与多药化疗的中位总生存期比较。补充图D：在倾向得分匹配后，辅助化疗与新辅助化疗的中位总生存期比较。补充图E：在（A）MSI-H和（B）MSI-L条件下，根据治疗方式的中位总生存期。补充图F：（A）MSI-H和（B）MSI-L条件下，单药化疗与多药化疗的中位总生存期比较。补充图G：（A）MSI-H和（B）MSI-L条件下，辅助化疗与新辅助化疗的中位总生存期比较。补充表A：根据倾向得分匹配后的治疗方式，肝转移性CRC患者的基线特征。补充表B：在倾向得分匹配后，排除术后90天内死亡的患者，根据治疗方式的肝转移性CRC患者的基线特征。